Medical Condition News

RSS

Highlights from Mayo Clinic's Discovery's Edge research magazine

Here are highlights from the winter issue of Discovery's Edge, Mayo Clinic's research magazine.

24 Dec 2009

American Diabetes Association lauds passage of health reform in the Senate

The American Diabetes Association issues the following statement about the passing of HR 3590 The Patient Protection and Affordable Care Act.

24 Dec 2009

New book on caries management

The International Caries Detection and Assessment System (ICDAS) offers clinical criteria and codes, together with a framework to support and enable personalized comprehensive caries management for improved long-term health outcome. Based on the ICDAS, this publication provides an up-to-date synthesis of the fields of detection, assessment, diagnosis and monitoring of caries.

24 Dec 2009

Peritoneal dialysis updates

The importance of peritoneal dialysis (PD) in the therapy of chronic kidney disease has been steadily increasing. The simultaneous advancement in clinical practice and basic research has increased overall knowledge and led to significant progress in the safe and adequate application of PD. Moreover, integration with other techniques in the therapy of uremia represents an important step in the optimization of the whole program of renal replacement therapy.

24 Dec 2009

UCB's Cimzia gains market share of Centocor's Simponi

BioTrends Research Group, Inc. announces the release of the final wave of LaunchTrends®: Simponi and Cimzia report. The survey was completed by U.S. Rheumatologists.

24 Dec 2009

E2F1 transcription factor inhibition reduces EGFR expression and invasive potential of melanoma cells

Inhibition of transcription factor E2F1 reduced epidermal growth factor receptor (EGFR) expression and reduced the invasive potential but not proliferation of metastatic melanoma cells, according to a brief communication published online December 23 in the Journal of the National Cancer Institute.

24 Dec 2009

Eli Lilly and Kowa Pharmaceuticals America to co-promote LIVALO in the U.S

Eli Lilly and Company (NYSE: LLY), Kowa Company, Limited, and Kowa's U.S. subsidiary, Kowa Pharmaceuticals America, Inc., today announced that Lilly and Kowa Pharmaceuticals America have entered into a co-promotion agreement in the United States to commercialize LIVALO® (pitavastatin). Lilly and Kowa have also entered into a licensing agreement in Latin America. LIVALO is a statin approved by the U.S. Food and Drug Administration (FDA) in August 2009 for the treatment of primary hyperlipidemia and mixed dyslipidemia.

24 Dec 2009

Study suggests routine evaluation does not predict prostate cancer

On the heels of the American Cancer Society's recent controversial response to breast and prostate cancer screenings guidelines, a new study from the Mayo Clinic has emerged analyzing the correlation between prostate-specific antigen (PSA) levels and prostate size. The study discovered that routine annual evaluation of prostate growth does not predict the development of prostate cancer.

24 Dec 2009

Key molecular switch linked to HD identified

Scientists have identified a key molecular switch that may drive the onset of Huntington's disease (HD), an incurable neurodegenerative disorder that leads to severe disruptions in muscle coordination and cognitive function. The research, published by Cell Press in the December 24 issue of the journal Neuron, enhances the understanding of HD pathogenesis and may direct new strategies for treating this devastating brain disease.

24 Dec 2009

Potential new therapeutic option for prevention of PD-associated neuropathology

Scientists have identified a synergistic interaction that disrupts normal intracellular transport mechanisms and leads to the accumulation of neuron-damaging clumps of protein associated with Parkinson's disease (PD), a neurodegenerative disorder that is characterized by a specific loss of neurons in the midbrain and brainstem. The research, published by Cell Press in the December 24 issue of the journal Neuron, identifies a new potential therapeutic option for preventing PD-associated neuropathology.

24 Dec 2009

Tips to minimize injuries during winter season

As we try to get outside and make the most of these cold winter months, it's important to use basic safety tips that help minimize injury. The Minnesota Chiropractic Association (MCA) offers the following tips to help keep your family injury free.

24 Dec 2009

Study evaluates anemia treatment approaches adopted by different specialists

BioTrends Research Group, Inc. published a syndicated research report, "TreatmentTrends®: Anemia in the United States," based on primary research conducted with approximately 400 physicians in clinical practice.

24 Dec 2009

Colcrys Patient Assistance Program introduced by URL Pharma

URL Pharma, Inc. announced the launch of the Colcrys® (colchicine, USP) Patient Assistance Program, an initiative that will allow patients with limited means to save on Colcrys prescriptions. This program reflects URL Pharma's ongoing commitment to helping ensure that all patients who rely on the company's medications are able to access them, regardless of economic status. Colcrys is indicated for the prevention and treatment of gout flares and for the treatment of Familial Mediterranean Fever (FMF).

24 Dec 2009

Rethink Autism offers research-based intervention tools for children with autism disorder

According to a study recently released by the Center for Disease Control and Prevention (CDC) and the Autism and Developmental Disabilities Monitoring Network, it is estimated that approximately 673,000 children aged 3-21 have been diagnosed with autism nationwide.

24 Dec 2009

Interdisciplinary approach essential for treating men’s' sexual dysfunction

Modern, couple-oriented treatment for male sexual dysfunction takes the psychosocial aspects of sex into account, as well as focussing on the purely physical aspects of the problem.

24 Dec 2009

FDA issues Pfizer a Complete Response letter for Lyrica GAD monotherapy treatment

Pfizer Inc. announced today that the Food and Drug Administration (FDA) issued a Complete Response letter regarding the company’s New Drug Application (NDA) for Lyrica® (pregabalin) capsules CV as a monotherapy treatment for generalized anxiety disorder (GAD). The FDA determined that the data contained in the NDA were insufficient to support approval.

24 Dec 2009

New compound may halt drug-resistant lung cancer

The ability to make, test, and map the atomic structure of new anti-cancer agents has enabled a team of Dana-Farber Cancer Institute scientists to discover a compound capable of halting a common type of drug-resistant lung cancer.

24 Dec 2009

Anti-inflammatory coxib medications inhibit aspirin's protective qualities

A new study conducted at Ben-Gurion University of the Negev (BGU) reveals that Celebrex and other anti-inflammatory coxib medications may counter the positive effects of aspirin in preventing blood clots.

24 Dec 2009

Study: Protein channel aids nerve sensors in controlling blood pressure

University of Iowa researchers have shown that a protein channel helps nerve sensors in blood vessels keep blood pressure in check. Without the protein channel, known as ASIC2, the sensors are unable to send the brain the signals it needs to properly control blood pressure.

24 Dec 2009

New energy receptor theory of brain function

Dr. Mitchell Earl Gibson, best-selling author, board-certified physician, and CEO of Tybro Publications, has proposed a new energy receptor theory of brain function that might explain the efficacy of mantras and prayer in human illness.

24 Dec 2009